Daptomycin for methicillin-resistant Staphylococcus aureus diabetic foot infections

Area of Science:

• Infectious Diseases
• Dermatology
• Pharmacology

Background:

• Diabetic foot infections (DFI) are severe and challenging to treat, particularly when caused by methicillin-resistant Staphylococcus aureus (MRSA).
• Vancomycin, the standard for MRSA, has shown reduced efficacy in some MRSA skin infections.
• This study evaluates daptomycin's effectiveness and safety for MRSA-DFI.

Purpose of the Study:

• To assess the clinical outcomes and safety profile of daptomycin in patients with diabetic foot infections caused by MRSA.
• To analyze factors influencing treatment success with daptomycin therapy.

Main Methods:

• Retrospective analysis of 79 patients with MRSA DFI from the Cubicin Outcomes Registry and Experience (2006-2009).
• Evaluated 74 patients receiving daptomycin, analyzing dosage, duration, and prior/concomitant antibiotic use.
• Assessed clinical success, treatment failure, and adverse events.

Main Results:

• Daptomycin was administered at a median dose of 4.8 mg/kg for a median of 15 days.
• Overall clinical success rate was 89.2%, with higher success in patients receiving daptomycin as initial therapy or who underwent surgery.
• 14 adverse events were reported in 11 patients, with two leading to discontinuation.

Conclusions:

• Daptomycin is a generally well-tolerated and effective treatment option for MRSA-DFI in a real-world setting.
• Consideration of anti-MRSA agents in first-line therapy is crucial to avoid inappropriate empirical treatment and improve outcomes.
• Daptomycin demonstrates promise for managing complex diabetic foot infections.